Used primarily in the pharmaceutical industry as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. It plays a critical role in the development of immunomodulatory drugs for treating hematological cancers such as multiple myeloma and myelodysplastic syndromes. Its structure enables selective binding to cereblon, facilitating the degradation of disease-causing proteins. Due to its reactivity and specificity, it is also employed in research settings for designing novel proteolysis-targeting chimeras (PROTACs) and molecular glues. Handling requires strict controls due to its potent biological activity and potential toxicity.